Skip to main content
Equibles
MANE logo

MANE · Veradermics, Inc

Track MANE — free

Use MANE with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about MANE

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$105.32 -5.91 (-5.31%) At close · Aug 20
Going-concern doubt — cleared Aug 11, 2026

The latest filing no longer states the doubt (first flagged May 12, 2026).

View the 10-Q filed Aug 11, 2026
Market Cap
$4.65B
Shares
41.78M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$105.32 Open$111.00 Day$101.69–111.39 Available close range$37.03–129.74 Avg vol 30d787K Short int4.8M · 11.5% float · 6.9d Short vol67% Last earningsAug 11, 2026 DataFeb 2026–Aug 2026 Filing10-Q · Aug 11

The closing range uses available history since Feb 4, 2026; less than a full year is stored.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 11, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Sell Momentum Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 14.9 · calm Equity put/call 0.52
      Technical
      price trend
      Sell
      50 / 200-day cross No cross
      Price vs 50-day avg −5%
      below
      RSI (14) 45
      neutral
      MACD trend Negative
      52-week position 74%
      mid-range
      Momentum
      relative strength
      Strong
      1-month return −9%
      trailing
      6-month return +130%
      trailing
      Relative strength +119%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50/200-day averages unavailable
      Institutional flow Accumulating
      +101% holders QoQ · +96 funds added
      Insider flow Distributing
      Net -$10.7M over 90 days · 100% sells
      Short interest Rising
      11.54% of float · ▲ +22.5% MoM · 6.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      163 holders — 13F breadth
      Squeeze score 72
      high risk · 0–100
      Fundamentals
      Weak
      EPS growth −202%
      Y/Y
      Free cash flow $-71.6M
      Balance sheet $21.8M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 100%
      annualized · 1-yr
      Max drawdown −21%
      past year
      ATR 6.9%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Sell
      1 · 4 · 0
      50 / 200-day cross
      No cross Neutral
      Price vs 50-day avg
      −5% Neutral
      RSI (14)
      45 Neutral
      MACD trend
      Negative Bearish
      52-week position
      74% Neutral
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50/200-day averages unavailable
      Institutional flow Accumulating
      +101% holders QoQ · +96 funds added
      Insider flow Distributing
      Net -$10.7M over 90 days · 100% sells
      Short interest Rising
      11.54% of float · ▲ +22.5% MoM · 6.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      163 holders — 13F breadth
      Price context
      position in its available closing range
      Range low $37 Now $105 · 74% Range high $130
      vs 50-day avg -5%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Net proceeds from IPO and follow-on offering (aggregate gross proceeds raised in 2026) $766.8M Q1 2026 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      MANE
      Veradermics, Inc
      this stock
      		$4.65B — — — 11.5%
      ONC
      BeOne Medicines Ltd.
      		 $557.05B +21.5% +22179.2% 856.5 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $136.93B +19.2% +46.2% 31.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $86.39B +7.1% +20.8% 20.8 3.3%
      MRNA
      Moderna, Inc.
      		 $69.62B +352.1% +4.3% — 12.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      163
      % held
      81.2%
      Net QoQ
      +8.0M sh
      Top holder
      SUVRETTA CAPITAL MANAGEME…
      Held Float
      View
      Held by Funds
      Fund positions
      60
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      4.8M
      Days to cover
      6.9d
      Change
      +884.0K sh
      View
      Short Volume
      Short vol %
      67%
      As of
      Aug 20, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      713
      Value
      $79.4K
      As of
      Jul 28, 2026
      View
      Off-Exchange
      Off-exchange %
      54.3%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$10.7M
      Buyers / Sellers
      0 / 1
      Buyers Sellers
      View
      Financials
      Financials
      Net income (FY)
      $-70.0M
      EPS diluted
      $-111.91
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 11, 2026
      This year
      13
      View
      Proposed Sales
      Value
      $74.1M
      Shares
      690.6K
      Filed
      Aug 19, 2026
      View
      Exempt Offerings
      Offering
      $30.0M
      Filed
      May 15, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 11, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      MANE -5.1% -9.1% +129.7% +0.3% —
      SPY -2.0% +3.3% +11.2% +2.1% +11.8%
      vs SPY -3.2% -12.4% +118.5% -1.8% —
      Key facts CIK 1827635 CUSIP 922967104 13F (30d) 161 filings 159 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)